Table 2.
Mean (± SD) Sleep Parameters in IFN-alpha-Treated and Control Subjects
| Interferon-alpha (n=19) |
Control (n=12) |
|||||
|---|---|---|---|---|---|---|
| Visit 1 | Visit 2 | Delta | Visit 1 | Visit 2 | Delta | |
| Sleep Period Time (min) | 488.9 (73.8) | 505.3 (53.7) | 16.4 (56.3)* | 511.7 (44.6) | 470.7 (58.5) | −41.0 (77.1) |
| Total Sleep Time (min) | 376.3 (61.1) | 345.1 (73.6) | −31.2 (72.7) | 387.5 (40.8) | 382.1 (46.3) | −5.5 (52.8) |
| WASO (min)† | 112.6 (62.6) | 160.2 (62.0)* | 47.6 (76.8)* | 124.2 (66.6) | 88.6 (35.8) | −35.6 (80.1) |
| Spontaneous Arousals | 90.2 (42.6) | 94.9 (53.4) | 4.7 (47.6) | 87.0 (31.0) | 92.7 (39.4) | 5.7 (21.8) |
| Total Sleep Efficiency† | 77.6 (11.4) | 68.0 (12.8)* | −9.6 (14.4)* | 76.3 (11.6) | 81.5 (6.2) | 5.2 (13.6) |
| Sleep Stages | ||||||
| Stage 1 (min) | 23.8 (8.2) | 31.5 (14.1) | 7.7 (13.8) | 29.2 (11.8) | 29.6 (13.3) | 0.4 (12.7) |
| Stage 2 (min)† | 203.9 (40.0) | 283.2 (51.8) | 79.3 (46.1)* | 215.9 (51.7) | 258.8 (41.7) | 42.8 (39.0) |
| Stage 3/4 (min)† | 62.1 (32.3) | 41.6 (26.2)* | −20.5 (24.9)* | 63.8 (32.9) | 61.9 (24.6) | −1.9 (15.2) |
| REM (min) | 86.1 (20.8) | 77.2 (26.1) | −8.9 (28.0) | 78.9 (16.5) | 80.8 (26.8) | 2.0 (29.4) |
| REM Latency (min)† | 81.3 (26.3) | 115.8 (67.8)* | 34.5 (64.4)* | 95.2 (41.1) | 81.5 (28.5) | −13.8 (46.0) |
SD-standard deviation; WASO-wake after sleep onset; REM-rapid eye movement sleep
*
- significantly different from respective Control value (p<0.05 using Fisher’s Least Significance Difference test);
†
- significant group X visit interaction (p<0.05); sleep efficiency=1− (wake after sleep onset/sleep period time)